AzTrials
AzTrials

Prostatic HyperplasiaTUMT-PAE-1NCT05686525

Clinical Trial on the Effectiveness of TUMT Compared to PAE in Reducing Severe LUTS in Men with BPH

A study testing Transurethral Microwave Thermotherapy and Prostate Artery Embolisation in people with Prostatic Hyperplasia and Lower Urinary Tract Symptoms, run by Copenhagen University Hospital, Rigshospitalet at 3 sites in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The TUMT-PAE-1 trial is a randomised clinical trial aiming to compare the effectiveness of transurethral microwave thermotherapy (TUMT) with prostatic artery embolisation (PAE) in reducing urinary symptoms caused by prostate gland enlargement. Read more about this study

Who is it for?
Ages 40 years and older, men only
What is being tested?
Transurethral Microwave Thermotherapy and Prostate Artery Embolisation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
220 participants
Where
3 sitesDenmark
Study dates
27 Oct 2022to Dec 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ability to understand and the willingness to sign an informed consent.
  • Diagnosis of LUTS secondary to BPH refractory to/contraindicated for medical treatment or not patient preference.
  • Severe urinary symptoms on IPSS (IPSS score ≥ 20).
  • Bladder outlet obstruction (BOO) is defined by Qmax ≤ 15ml/sec, based on uroflowmetry.
  • Prostate volume at minimum 50 ml measured by TRUS or MR.
  • Men with prostate cancer in Active Surveillance or Watchful Waiting who have LUTS due to a large BPH component are allowed.
  • Indwelling catheter or intermittent catheter is allowed. In this case baseline IPSS is 35 points.

Who cannot join

  • Active bladder cancer (patients with pTa low-grade tumors are allowed).
  • Previous pelvic radiation for cancer treatment.
  • Bladder stones (inclusion is allowed after removal).
  • Current urethral strictures or bladder neck contracture.
  • Neurogenic LUTS.
  • Symptomatic urinary tract infection at the time of intervention.
Show all 14Show fewer
  • Documented bacterial prostatitis in the last year.
  • Severe atheromatous disease or other pathology preventing catheter-based intervention (as rated on CT angiography by an interventional radiologist).
  • Allergy to iodinated contrast media.
  • Renal failure defined as estimated glomerular filtration rate (eGFR) < 35ml/min.
  • High bleeding risk (spontaneous international normalized ratio (INR) > 1.6).
  • Contraindication to conscious sedation (if requested by the patient).
  • Prostate median lobe defined by treating physician.
  • Urethral colliculus to bladder neck length <35mm.

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Anna Kristensen-Alvarez, MD contact

+4535456152

anna.kristensen-alvarez@regionh.dk

Denmark3 sites, 3 recruiting

  • Urological Research Unit, Rigshospitalet

    Copenhagen, Copenhagen N, 2200

    Anna Kristensen-Alvarez, MD, +4535456152, anna.kristensen-alvarez@regionh.dk

    Andreas Røder, Prof.,MD,PhD, +4535456152, andreas.roeder@regionh.dk

    Recruiting

  • Department of Urology, Herlev-Gentofte Hospital

    Gentofte Municipality, Hellerup, 2900

    Anna Kristensen-Alvarez, MD, +4535456152, anna.kristensen-alvarez@regionh.dk

    Mikkel M Fode, Prof.,MD,PhD, +4538680140, mikkel.mejlgaard.fode@regionh.dk

    Recruiting

  • Zealand University Hospital

    Roskilde, 4000

    Anna Kristensen-Alvarez, MD, +4535456152, anna.kristensen-alvarez@regionh.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Non-inferiority, Randomised, Open-label Clinical Trial on the Effectiveness of Transurethral Microwave Thermotherapy Compared to Prostatic Artery Embolisation in Reducing Severe Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia

The TUMT-PAE-1 trial is a randomised clinical trial aiming to compare the effectiveness of transurethral microwave thermotherapy (TUMT) with prostatic artery embolisation (PAE) in reducing urinary symptoms caused by prostate gland enlargement. The assessment will be done by patient reported and functional outcome measures. The primary purpose is to evaluate the urinary symptoms six months after the procedure, measured by the International Prostate Symptom Score (IPSS).

Read the detailed description

One fourth of men older than 70 years have moderate to severe lower urinary tract symptoms (LUTS) that impair their quality of life (QOL). This is most frequently caused by benign prostatic hyperplasia (BPH). Transurethral resection of the prostate (TURP) is still regarded as the gold standard for surgical treatment of BPH. However, TURP is only an option for patients fit for general anesthesia and can result in complications. Consequently, several less invasive procedures have been developed, as prostatic artery embolization (PAE) and transurethral microwave thermotherapy (TUMT).

The objective of this clinical trial is to assess if transurethral microwave thermotherapy (TUMT) is non-inferior to prostatic artery embolization (PAE) in reducing lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). The primary aim is to compare LUTS 6 months after the TUMT and PAE procedures, measured by the International Prostate Symptom Score (IPSS). Both treatments have previously been shown to reduce LUTS with a similar post-procedure outcome in mean IPSS. However, the previous studies differed in baseline characteristics thus it is currently unknown if they perform equally well. Secondary objectives include comparison of patient reported and functional outcomes at short- and long-term follow-up. The trial importantly includes analysis of patient-reported outcome measures of satisfaction with treatment, quality of life, incontinence, erectile and ejaculatory function, as well as evaluation of uroflowmetry, prostate volume, prostate specific antigen, catheter dependency, side effects, hospital admissions and re-treatment rate.

This study is designed as a multi-centre, non-inferiority, open label randomised clinical trial. Patients will be randomised with a 1:1 allocation ratio between treatments using the randomisation module in REDCap. The primary outcome is expected to be evaluated by a 95% confidence interval against the predefined threshold of +3 points in IPSS for inferiority. Secondary outcomes will be presented descriptively and assessed by students T-test, Chi-squared test and linear mixed models. The patient reported outcomes will be obtained by standardized validated surveys and functional outcomes, side effects and re-treatment rates will be measured at 1 month, 3 months, 6 months, 1 year, 2 years and 5 years post procedure. Assuming a difference in mean IPSS after treatment of 1 point with an standard deviation (SD) of 5 and a non-inferiority margin set at the border for a clinically non-meaningful difference of 3 points, the calculated sample size was 100 patients per arm. To compensate for 10% drop-out the study will include 220 patients. An interim analysis will be performed for every 50 cases.

TUMT and PAE are minimally invasive procedures performed in an outpatient setting that have been shown to reduce LUTS in a similar magnitude. To date there are no randomised clinical trials comparing PAE to TUMT, which is problematic as the most prominent problem with minimally invasive BPH treatment is the lack of proper selection of candidates for a specific procedure. Non-inferiority of TUMT to PAE is expected, with analysis of the secondary outcomes, the investigators aspire to contribute to a better understanding of patient selection for either treatment.

Being tested
Transurethral Microwave Thermotherapy, Prostate Artery Embolisation
Keywords
Embolization, Therapeutic, Prostatic Artery Embolization, Transurethral Microwave Thermotherapy, Patient Reported Outcome Measures
Medical subject headings
Prostatic Hyperplasia, Lower Urinary Tract Symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transurethral Microwave ThermotherapyProcedure or surgery

    Also called TUMT

    TUMT is performed by a urologist and/or a trained urological nurse. In TUMT a specially designed instrument that sends out microwave energy is inserted inside the prostate through the urethra. Cooling fluid circulates the instrument to prevent heat from damaging the wall of the urethra. To prevent the temperature from getting too high outside the prostate a temperature sensor is inserted into the patient's rectum and at the penoscrotal angle. If the temperature reaches the safety limit the microwave generator's output will be shut off automatically. Microwave is then used to heat the prostate (preferably to 50-60 degrees Celsius) and destroy hyperplastic prostate tissue. As the prostate heals it will shrink and reduce the blockage of urine flow and the symptoms of BPH.

  • Prostate Artery EmbolisationProcedure or surgery

    Also called PAE

    In PAE an interventional radiologist will insert a small catheter into the vessels that supply blood to the prostate. An arteriogram is done to map the blood vessels feeding the prostate. Tiny embolization particles are injected through the catheter and into the blood vessels to reduce the blood supply to the prostate. This procedure is intended bilaterally at both sides of the prostate. Following the procedure, the prostate will begin to shrink reducing the symptoms of BPH.

Study groups in NCT05686525
Study groupRoleWhat they receive
TUMTExperimentalIn this arm, patients will undergo Transurethral Microwave Thermotherapy (TUMT) where microwave energy is used to destroy the prostate tissue. TUMT is performed under local anaesthesia. Usually, the patient can be discharged from the hospital on the same day. If the patient cannot be discharged on the same day, he will be admitted to the urological ward. After the treatment, a transurethral catheter is inserted. This will be removed at the physician's discretion when spontaneous voiding is achieved with an acceptable residual volume (in general <100-150 ml), typically within four weeks.
Receives: Procedure: Transurethral Microwave Thermotherapy
PAEExperimentalIn this arm, patients will undergo prostate artery embolisation (PAE) where blocking the blood flow to the prostate causes it to shrink. PAE is performed under local anaesthesia. Usually, the patient can be discharged from the hospital on the same day. If the patient cannot be discharged on the same day, he will be admitted to the urological ward. Patients with a permanent catheter prior to PAE will keep the catheter up to four weeks after the procedure.
Receives: Procedure: Prostate Artery Embolisation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean IPSS of the TUMT and PAE arm 6 months after the procedure

    The International Prostate Symptom Score (IPSS) is a validated, reproducible, patient-reported outcome measure to assess lower urinary tract symptoms (LUTS) severity and response to treatment. The IPSS is made up of 7 questions and possible scores range from 0 to 35. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and a score of 20 to 35 indicates severe symptoms. If the patient has an indwelling catheter the IPSS score is 35.

    Measured: 6 months post-procedure.

Secondary outcomes (18)

  1. Mean IPSS of the TUMT and PAE arm at 3,12, 24 and 60 months after the procedure

    The International Prostate Symptom Score (IPSS) is a validated, reproducible, patient-reported outcome measure to assess lower urinary tract symptoms (LUTS) severity and response to treatment. The IPSS is made up of 7 questions and possible scores range from 0 to 35. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and a score of 20 to 35 indicates severe symptoms. If the patient has an indwelling catheter the IPSS score is 35.

    Measured: 3, 12, 24 and 60 months post-procedure.

  2. Mean IPSS-QoL score of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure

    The International Prostate Symptom Score-Quality of Life (IPSS-QoL) is a validated, reproducible, patient-reported outcome measure to assess the frequency of symptoms from urinary problems and associated QoL. It is a validated screening tool for depression. The IPSS-QoL has 1 item that rates QoL (feelings if current symptoms lasted for life) on a scale ranging from 0 (delighted) to 6 (terrible).

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  3. Mean EQ-5D-5L score of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure

    The EQ-5D is a broadly used, reliable and generic health utility instrument. It has five dimensions each with one item: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D contains a visual analog scale (VAS) where the patient rates his health from 0 (worst imaginable) to 100 (best imaginable). Treatment effects will be assessed by measuring health status with EQ-5D at different points in time.

    The EQ-5D is the most widely applied instrument for health-economic assessment worldwide. Its index values are used in the estimation of quality-adjusted life year (QALY) gains in economic evaluations of healthcare interventions. EQ-5D profile and EQ VAS data provide additional evidence on the relative effectiveness of healthcare interventions. A health economic evaluation of the two procedures will be performed using the EQ-5D-5L score of the two arms during the follow up period.

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  4. Mean BII score of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure

    The BPH Impact Index (BII) is a self-reported, validated, disease-specific instrument for quantifying the interference of lower urinary tract symptoms(LUTS) on the patients mental health and activity. As a measure of Quality of Life (QoL), it is used to determine treatment outcomes in men with symptomatic benign prostatic hyperplasia. The BII is a four-item questionnaire that addresses discomfort, worry, bother, and functional interference from any urinary problems. It is scored by addition yielding a range from 0 (no impact) to 13 (great impact).

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  5. Mean patient satisfaction with the TUMT and PAE treatment by Likert scale 1 and 3 months after the procedure

    The patient's satisfaction with the treatment will be evaluated by a bipolar Likert-type scale. The format of the questionnaire is that of a typical five-level Likert item. Possible scores range from 1 (completely satisfied) to 5 (completely unsatisfied).

    Measured: 1 and 3 months post-procedure.

  6. Mean ICIQ-UI-SF scores of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure

    The International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) is a validated, patient reported outcome measure (PROM) for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence. It consists of four items and possible scores range from 1 - 5 (slight), 6 - 12 (moderate), 13 - 18 (severe) and 19 - 21 (very severe).

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  7. Mean IIEF-EF scores of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure

    The International Index of Erectile Function - Erectile Function (IIEF-EF) domain score is a self-administered questionnaire used to measure erectile performance and assess disease severity in efficacy trials concerning erectile dysfunction(ED). The IIEF-EF has six items (items 1-5 and 15 of the IIEF). The EF domain possesses favorable statistical properties as a diagnostic tool in distinguishing between men with and without ED and classifying levels of ED severity. It has the requisites to detect treatment-related changes in patients with ED.

    The maximum score of the erectile function domain of the IIEF is 30. A lower score would mean more problems with erectile function.

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  8. Mean DAN-PSSsex score of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure

    The Danish Prostate Symptom Score(DAN-PSS) is a validated symptom scale for assessing the severity of symptoms among patients with lower urinary tract complaints suggestive of benign prostatic hyperplasia. The Danish Prostate Symptom Score Sexual items (DAN-PSSsex) is a validated instrument to determine sexual function (including erectile and ejaculatory function) and its impact on the well-being of the patient. The DAN-PSSsex consists of 3 items each containing 2 questions A and B, where A refers to a symptom and B refers to the bother of the symptom. The total score is the sum of the multiplication of A and B. Possible scores range from 0 (no problem with sexual function) to 27 (very bothered by sexual function).

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  9. Mean prostate volume (PV), measured by TRUS, of the TUMT and PAE arm at 3, 6, 12 and 24 months after the procedure

    Prostate volume is linked to negative outcomes related to BPH and an indicator of response to the treatment procedure. Prostate volume will be measured in mL by Transrectal ultrasound (TRUS). TRUS prostate volume estimates are consistent with volumes of radical prostatectomy pathology reports.

    Measured: Baseline, 3, 6, 12 and 24 months post-procedure.

  10. Mean maximum flow rate by uroflowmetry of the TUMT and PAE arm at 3, 6, 12 and 24 months after the procedure

    Uroflowmetry will be used to measure maximum flow rate. Uroflowmetry is a non-invasive procedure used to measure the flow of urine throughout micturition and assist in the diagnosis of lower urinary tract dysfunctions. It provides useful information about total voiding function and is used for BPH diagnosis and evaluation of treatment response. Qmax is measured in mL/second, the Qmax is the value of the highest flow rate measured during the test. Qmax ≥ 15 mL/s and a bell-shaped curve indicate normal voiding. Qmax < 15 mL/s indicates a week flow. The lower Qmax the weaker the flow. If the patient has an indwelling catheter and cannot perform a uroflowmetry, the Qmax will be set to zero.

    Measured: Baseline, 3, 6, 12 and 24 months post-procedure.

  11. Mean voided volume by uroflowmetry of the TUMT and PAE arm at 3, 6, 12 and 24 months after the procedure

    Voided volume of the uroflowmetry is measured in ml. Uroflowmetry is a non-invasive procedure used to measure the flow of urine throughout micturition and assist in the diagnosis of lower urinary tract dysfunctions. It provides useful information about total voiding function and is used for BPH diagnosis and evaluation of treatment response. In most cases a uroflowmetry would only be valid if the voided volume in ml is above 150.

    Measured: Baseline, 3, 6, 12 and 24 months post-procedure.

  12. Mean residual urine volume, of the TUMT and PAE arm at 3, 6, 12 and 24 months after the procedure

    Transabdominal ultrasound is an accurate non-invasive instrument for assessing postvoiding residual urine. A post-void residual volume helps in the evaluation of urinary outlet obstruction and BPH treatment response.

    Measured: Baseline, 3, 6, 12 and 24 months post-procedure.

  13. Number of catheterization events of the TUMT and PAE arm at 3, 6, 12, 24 and 60 months after the procedure.

    Catheterization will be expressed as reason for placement, duration and frequency (in case of intermittent catheterization) of catheterization. Both the placement of an indwelling urinary catheter and the use of intermittent catheterization will be described. If an indwelling catheter was placed after the procedure, post-procedure duration of catheterization will be defined as days from the procedure till indwelling catheter cessation. Catheterization for any other reason during the follow-up period will also be evaluated. The need of catheterization can be used in the overall determination of the effectiveness of the treatment.

    Measured: 3, 6, 12, 24 and 60 months post-procedure.

  14. Mean prostate-specific antigen (PSA) of the TUMT and PAE arm at 3, 6, 12 and 24 months after the procedure

    A blood sample for PSA will be taken by venipuncture sampling. The absolute value of serum PSA (ng/mL) has good predictive value for determination of prostate volume. Continues PSA measurements assist in the detection of any de novo prostate cancer or progression of patients in active surveillance or watchful waiting.

    Measured: 3, 6, 12 and 24 months post-procedure.

  15. Mean creatinine of the TUMT and PAE arm at 3, 6, 12 and 24 months after the procedure

    A rise in serum creatinine can be a result of benign prostate hyperplasia (BPH) with urinary retention. Serum creatinine also aid in the identification of any affection of the kidney from the procedures.

    Measured: 3, 6, 12 and 24 months post-procedure.

  16. De novo use of pharmacological LUTS treatment in the TUMT and PAE arms

    Type and rate of de novo pharmacological LUTS treatment will be described and compared in between the two arms.

    Measured: 12, 24 and 60 months post-procedure.

  17. Surgical re-treatment in the TUMT and PAE arms

    The type and rate of surgical re-treatment will be described and compared in between the two arms.

    Measured: 12, 24 and 60 months post-procedure.

  18. Incidence of side effects of the TUMT and PAE arms during the first 3 months after the procedure

    The following side effects will be assessed: urinary tract infection, acute urinary retention, dysuria, haematuria, access-site hematoma, pseudoaneurysm and post-embolization syndrome (defined as occurring within 48h after surgery and consisting of influenza-like symptoms, pain, nausea, dysuria and transient worsening of LUTS). All side effects will be classified according to the Clavien-Dindo system.

    Hospital admission and hospitalization time will also be compared in between the two arms.

    All serious adverse events (SAE) will be reported with intensity and causality. A SAE is defined as all adverse event or adverse reaction that fulfils any of the following criteria: results in death, is life-threatening, requires hospitalization or prolonging of existing hospitalization, or results in persistent or significant disability or incapacity.

    Measured: 3 months post-procedure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jan 2023
  2. Study start27 Oct 2022
  3. Primary completionDec 2030 (estimated)
  4. Study completionDec 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study will randomize approximately 220 patients with an anticipated 10% dropout (N = 200). The study will assign patients in a 1:1 manner to either Arm 1: TUMT or Arm 2: PAE.
Masking
None (open label)
Enrolment
220 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05686525
Sponsor's protocol ID
H-22001990
Other IDs
P-2022-183
Acronym
TUMT-PAE-1
Status last verified
Jan 2025
First submitted
8 Nov 2022
Last updated
13 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: All study data including study protocol, statistical analysis plan, informed consent form, and clinical study report can be shared when a proper agreement is formed according to the European Union (EU) General Data Protection Regulation (GDPR) protection statement.

Publications

  • Kristensen-Alvarez A, Fode M, Stroomberg HV, Nielsen KK, Arch A, Lonn LB, Taudorf M, Widecrantz SJ, Roder A. Non-inferiority, randomised, open-label clinical trial on the effectiveness of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia: study protocol for the TUMT-PAE-1 trial. Trials. 2024 Sep 2;25(1):574. doi: 10.1186/s13063-024-08409-x.

    PubMed 39223593

Questions about this trial

What is this clinical trial studying?

A study testing Transurethral Microwave Thermotherapy and Prostate Artery Embolisation in people with Prostatic Hyperplasia and Lower Urinary Tract Symptoms, run by Copenhagen University Hospital, Rigshospitalet at 3 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Anna Kristensen-Alvarez, MD (+4535456152, anna.kristensen-alvarez@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean IPSS of the TUMT and PAE arm 6 months after the procedure (time frame: 6 months post-procedure.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05686525, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in